Fda Approval Applications

Creso Pharma’s Halucenex engages HeteroGeneity ahead of US entry

Finfeed Archived May 26, 2021

Creso Pharma's target acquisition group Halucenex has entered into an agreement with consultancy group, HetereoGeneity